Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 4 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
Ovarian Cancer (2nd line maintenance) *
Mainland China, HK & Macau (China)
Ovarian Cancer (1st line maintenance)*
Mainland China
Ovarian Cancer (late line treatment)*
Gastric Cancer (combo with tebotelimab)[1, 12]
Other solid tumors[2] (I/O[3] combo)
Glioblastoma (GBM) *
Hong Kong (China), mainland China
Mesothelioma* (Optune Lua)
NSCLC[4]
Brain Metastases
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer[1]
Liver Cancer
Infectious Disease and Autoimmune
Note: [1] China-only trials; [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.